Merck & Co., Inc. Net Income (Loss) Available to Common Stockholders, Basic
Merck & Co., Inc. (MRK) reported Net Income (Loss) Available to Common Stockholders, Basic of -$1.33 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-07
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$1.33B, a 130.16% decline year-over-year.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$4.24B, a 183.48% decline year-over-year.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $2.96B, a 20.84% decline year-over-year.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $5.79B, a 83.24% increase year-over-year.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $18.25B, a 6.64% increase from fiscal 2024.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was $17.12B, a 4589.59% increase from fiscal 2023.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was $365.00M, a 97.49% decline from fiscal 2022.
- Merck & Co., Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $14.52B, a 11.27% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.33B 10-Q · filed 2026-08-07 | -$5.58B 10-Q · filed 2026-08-07 | -$2.61B derived: sum of 3 quarters · filed 2026-08-07 | $3.17B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | -$4.24B 10-Q · filed 2026-05-04 | -$1.28B derived: sum of 2 quarters · filed 2026-05-04 | $4.51B derived: sum of 3 quarters · filed 2026-05-04 | $8.94B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $2.96B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.75B derived: sum of 2 quarters · filed 2026-02-24 | $13.18B derived: sum of 3 quarters · filed 2026-08-07 | $18.25B 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $5.79B 10-Q · filed 2025-11-05 | $10.21B derived: sum of 2 quarters · filed 2026-08-07 | $15.29B 10-Q · filed 2025-11-05 | $19.03B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $4.43B 10-Q · filed 2026-08-07 | $9.51B 10-Q · filed 2026-08-07 | $13.25B derived: sum of 3 quarters · filed 2026-08-07 | $16.41B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $5.08B 10-Q · filed 2026-05-04 | $8.82B derived: sum of 2 quarters · filed 2026-05-04 | $11.98B derived: sum of 3 quarters · filed 2026-05-04 | $17.43B derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $3.74B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.90B derived: sum of 2 quarters · filed 2026-02-24 | $12.36B derived: sum of 3 quarters · filed 2026-02-24 | $17.12B 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $3.16B 10-Q · filed 2025-11-05 | $8.61B derived: sum of 2 quarters · filed 2025-11-05 | $13.37B 10-Q · filed 2025-11-05 | $12.15B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $5.46B 10-Q · filed 2025-08-05 | $10.22B 10-Q · filed 2025-08-05 | $8.99B derived: sum of 3 quarters · filed 2026-02-24 | $13.74B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $4.76B 10-Q · filed 2025-05-02 | $3.54B derived: sum of 2 quarters · filed 2026-02-24 | $8.28B derived: sum of 3 quarters · filed 2026-02-24 | $2.31B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | -$1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.52B derived: sum of 2 quarters · filed 2026-02-24 | -$2.46B derived: sum of 3 quarters · filed 2026-02-24 | $365.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $4.75B 10-Q · filed 2024-11-06 | -$1.23B derived: sum of 2 quarters · filed 2024-11-06 | $1.59B 10-Q · filed 2024-11-06 | $4.61B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | -$5.97B 10-Q · filed 2024-08-05 | -$3.15B 10-Q · filed 2024-08-05 | -$137.00M derived: sum of 3 quarters · filed 2025-02-25 | $3.11B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $2.82B 10-Q · filed 2024-05-03 | $5.84B derived: sum of 2 quarters · filed 2025-02-25 | $9.09B derived: sum of 3 quarters · filed 2025-02-25 | $13.03B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $3.02B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $6.26B derived: sum of 2 quarters · filed 2025-02-25 | $10.21B derived: sum of 3 quarters · filed 2025-02-25 | $14.52B 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $3.25B 10-Q · filed 2023-11-03 | $7.19B derived: sum of 2 quarters · filed 2023-11-03 | $11.50B 10-Q · filed 2023-11-03 | $15.26B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $3.94B 10-Q · filed 2023-08-07 | $8.25B 10-Q · filed 2023-08-07 | $12.01B derived: sum of 3 quarters · filed 2024-02-26 | $16.58B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $4.31B 10-Q · filed 2023-05-05 | $8.07B derived: sum of 2 quarters · filed 2024-02-26 | $12.63B derived: sum of 3 quarters · filed 2024-02-26 | $14.18B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $3.76B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $8.32B derived: sum of 2 quarters · filed 2024-02-26 | $9.87B derived: sum of 3 quarters · filed 2024-02-26 | $13.05B 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $4.57B 10-Q · filed 2022-11-03 | $6.11B derived: sum of 2 quarters · filed 2022-11-03 | $9.29B 10-Q · filed 2022-11-03 | $7.20B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $1.54B 10-Q · filed 2022-08-05 | $4.72B 10-Q · filed 2022-08-05 | $2.63B derived: sum of 3 quarters · filed 2023-02-24 | $5.57B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $3.18B 10-Q · filed 2022-05-05 | $1.08B derived: sum of 2 quarters · filed 2023-02-24 | $4.03B derived: sum of 3 quarters · filed 2023-02-24 | |||||
| 2020-12-31 | -$2.09B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $847.00M derived: sum of 2 quarters · filed 2023-02-24 | $7.07B 10-K · filed 2023-02-24 | |||||
| 2020-09-30 | $2.94B 10-Q · filed 2021-11-05 | $9.16B 10-Q · filed 2021-11-05 | ||||||
| 2019-12-31 | $9.84B 10-K · filed 2022-02-25 | |||||||
| 2014-12-31 | $11.92B 10-K · filed 2015-02-27 | |||||||
| 2013-12-31 | $781.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $1.91B derived: sum of 2 quarters · filed 2015-02-27 | $2.81B derived: sum of 3 quarters · filed 2015-02-27 | $4.40B 10-K · filed 2015-02-27 | ||||
| 2013-09-30 | $1.12B 10-Q · filed 2013-11-07 | $2.03B derived: sum of 2 quarters · filed 2013-11-07 | $3.62B 10-Q · filed 2013-11-07 | $4.53B derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-06-30 | $906.00M 10-Q · filed 2013-08-07 | $2.50B 10-Q · filed 2013-08-07 | $3.41B derived: sum of 3 quarters · filed 2015-02-27 | $5.14B derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-03-31 | $1.59B 10-Q · filed 2013-05-09 | $2.50B derived: sum of 2 quarters · filed 2015-02-27 | $4.23B derived: sum of 3 quarters · filed 2015-02-27 | $6.02B derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2012-12-31 | $908.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $2.64B derived: sum of 2 quarters · filed 2015-02-27 | $4.43B derived: sum of 3 quarters · filed 2015-02-27 | $6.17B 10-K · filed 2015-02-27 | ||||
| 2012-09-30 | $1.73B 10-Q · filed 2013-11-07 | $3.52B derived: sum of 2 quarters · filed 2013-11-07 | $5.26B 10-Q · filed 2013-11-07 | $6.77B derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-06-30 | $1.79B 10-Q · filed 2013-08-07 | $3.53B 10-Q · filed 2013-08-07 | $5.04B derived: sum of 3 quarters · filed 2014-02-27 | $6.73B derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-03-31 | $1.74B 10-Q · filed 2013-05-09 | $3.25B derived: sum of 2 quarters · filed 2014-02-27 | $4.93B derived: sum of 3 quarters · filed 2014-02-27 | $6.95B derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2011-12-31 | $1.51B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $3.20B derived: sum of 2 quarters · filed 2014-02-27 | $5.22B derived: sum of 3 quarters · filed 2014-02-27 | $6.26B 10-K · filed 2014-02-27 | ||||
| 2011-09-30 | $1.69B 10-Q · filed 2012-11-09 | $3.71B derived: sum of 2 quarters · filed 2012-11-09 | $4.75B 10-Q · filed 2012-11-09 | $4.22B derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | $2.02B 10-Q · filed 2012-08-07 | $3.06B 10-Q · filed 2012-08-07 | $2.53B derived: sum of 3 quarters · filed 2013-02-28 | $2.87B derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | $1.04B 10-Q · filed 2012-05-08 | $512.00M derived: sum of 2 quarters · filed 2013-02-28 | $852.00M derived: sum of 3 quarters · filed 2013-02-28 | $1.60B derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | -$528.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$188.00M derived: sum of 2 quarters · filed 2013-02-28 | $561.00M derived: sum of 3 quarters · filed 2013-02-28 | $859.00M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | $340.00M 10-Q · filed 2011-11-08 | $340.40M 10-Q · filed 2010-11-08 | $1.09B derived: sum of 2 quarters · filed 2011-11-08 | $1.39B 10-Q · filed 2011-11-08 | $1.39B 10-Q · filed 2010-11-08 | $7.85B derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-06-30 | $749.00M 10-Q · filed 2011-08-08 | $749.50M 10-Q · filed 2010-08-06 | $1.05B 10-Q · filed 2011-08-08 | $1.05B 10-Q · filed 2010-08-06 | $7.51B derived: sum of 3 quarters · filed 2012-02-28 | $10.93B derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-03-31 | $298.00M 10-Q · filed 2011-05-09 | $6.77B derived: sum of 2 quarters · filed 2012-02-28 | $10.18B derived: sum of 3 quarters · filed 2012-02-28 | $11.73B derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2009-12-31 | $6.47B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $9.88B derived: sum of 2 quarters · filed 2012-02-28 | $11.43B derived: sum of 3 quarters · filed 2012-02-28 | $12.85B 10-K · filed 2012-02-28 | $12.90B 10-K · filed 2010-03-01 | |||
| 2009-09-30 | $3.41B 10-Q · filed 2010-11-08 | $477.00M 10-Q · filed 2009-10-29 | $4.96B derived: sum of 2 quarters · filed 2010-11-08 | $6.39B 10-Q · filed 2010-11-08 | $1.88B 10-Q · filed 2009-10-29 | |||
| 2009-06-30 | $1.55B 10-Q · filed 2010-08-06 | $633.00M 10-Q · filed 2009-07-24 | $2.97B 10-Q · filed 2010-08-06 | $1.40B 10-Q · filed 2009-07-24 | ||||
| 2008-12-31 | $6.51B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $7.09B derived: sum of 2 quarters · filed 2011-02-28 | $7.51B derived: sum of 3 quarters · filed 2011-02-28 | $7.79B 10-K · filed 2011-02-28 | $7.81B 10-K · filed 2010-03-01 | |||
| 2008-09-30 | $576.00M 10-Q · filed 2009-10-29 | $1.00B derived: sum of 2 quarters · filed 2009-10-29 | $1.28B 10-Q · filed 2009-10-29 | |||||
| 2008-06-30 | $424.00M 10-Q · filed 2009-07-24 | $700.00M 10-Q · filed 2009-07-24 | ||||||
| 2007-12-31 | $3.28B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |